Emcure, Sanofi tie up for anti-diabetic range
Emcure will exclusively distribute and promote the range of products, which include brands like Amaryl and Cetapin.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 days ago
- Time of India
Emcure, Sanofi tie up for anti-diabetic range
New Delhi: Emcure Pharma and Sanofi India announced that they entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India, effective immediately. Emcure will exclusively distribute and promote the range of products, which include brands like Amaryl and Cetapin.
&w=3840&q=100)
Business Standard
5 days ago
- Business Standard
Stock Market LIVE: Sensex falls 190 pts, Nifty below 25,200; Angel One up 2%, Tech Mahindra down 2%
Sensex Today | Stock Market LIVE on Thursday, July 17, 2025: In the broader markets, the Nifty MidCap index erased gains to trade 0.07 per cent lower, while the Nifty SmallCap index held onto its gain 10:51 AM Stock Market LIVE Updates: Emcure Pharma, Sanofi India shares edge higher; what's behind the move? Stock Market LIVE Updates: Shares of pharma major Emcure Pharmaceuticals rose over 2 per cent to hit an intraday high of ₹1,394.8 on the National Stock Exchange (NSE) after the company announced a distribution and promotion partnership with Sanofi India on Wednesday. At 9:30 AM, the stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5. In comparison, the benchmark NSE Nifty50 index was trading marginally down by 15.5 points at 25,196.55 levels. The total market capitalisation of Emcure Pharmaceuticals stood at ₹26,216.58 crore. READ MORE 10:21 AM Stock Market LIVE Updates: Will Tech Mahindra stock rise or fall post Q1 performance Stock Market LIVE Updates: Tech Mahindra stock slipped over 2 per cent in early trade to a low of ₹1,572 on Thursday a day after reporting the June (Q1) quarter results. The IT firm - Tech Mahindra reported a 33.9 per cent growth in consolidated net profit at ₹1,140.60 crore for Q1FY26 as against ₹851.50 crore reported a year ago. Revenue from operations rose by 2.7 per cent year-on-year (YoY) to ₹13,351.20 crore from ₹13,005.50 crore. However, on a sequential basis (quarter-on-quarter) net profit was down 2.2 per cent, and revenue dipped 0.2 per cent. READ MORE 9:30 AM Stock Market LIVE Updates: Sector check 9:22 AM Stock Market LIVE Updates: Sensex, Nifty flat after market opens Stock Market LIVE Updates: BSE Sensex was flat, below 82,650-mark after the market opened. Similary, NSE Nifty50 was below 25,250-level, down 7 points. 9:10 AM Stock Market LIVE Updates: Sensex up over 100 pts in pre-open Connect with us on WhatsApp
&w=3840&q=100)
Business Standard
5 days ago
- Business Standard
Emcure Pharma, Sanofi India shares edge higher; what's behind the move?
Emcure Pharmaceuticals share price today: Shares of pharma major Emcure Pharmaceuticals rose over 2 per cent to hit an intraday high of ₹1,394.8 on the National Stock Exchange (NSE) after the company announced a distribution and promotion partnership with Sanofi India on Wednesday. At 9:30 AM, the stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5. In comparison, the benchmark NSE Nifty50 index was trading marginally down by 15.5 points at 25,196.55 levels. The total market capitalisation of Emcure Pharmaceuticals stood at ₹26,216.58 crore. Shares of Sanofi India also gained around 1.5 per cent to hit an intraday high of ₹5,975. At the time of writing, the stock was quoting 1.2 per cent higher at ₹5,956.5. Emcure Pharmaceuticals and Sanofi India have entered a distribution and promotion partnership aimed at expanding access to Sanofi's oral anti-diabetic (OAD) products across India. Effective immediately, Emcume will exclusively distribute and promote Sanofi's OAD range of products, including established brands like Amaryl and Cetapin. However, Sanofi India will continue to own and manufacture these brands across Sanofi's plants in India and internationally. "Emcure will leverage its strengths to engage healthcare professionals and expand the reach of these therapeutic solutions for patients who need them across all of India," the company said in an exchange filing. "With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them. This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country,' said Satish Mehta, chief executive officer and managing director at Emcure Pharmaceuticals. About Emcure Pharma Headquartered in Pune, Emcure Pharmaceuticals is engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Emcure develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, Emcure is ranked as the 12th largest pharma company in India in terms of domestic sales for MAT June 2024. The company has a presence in more than 70 countries globally, including Europe and Canada.
